My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 321

    1.

    Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program.

    Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R; Diabetes Prevention Program.

    Diabetes. 2008 Apr;57(4):980-6. Epub 2008 Jan 11.PMID: 18192541 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.

    Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, Price D; Diabetes Prevention Program Research Group.

    Diabetes Care. 2009 Apr;32(4):726-32. Epub 2009 Jan 26.PMID: 19171717 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Relationship of body size and shape to the development of diabetes in the diabetes prevention program.

    [No authors listed]

    Obesity (Silver Spring). 2006 Nov;14(11):2107-17.PMID: 17135629 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.

    Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X, Fowler S, Kahn SE; Diabetes Prevention Program Research Group.

    J Clin Endocrinol Metab. 2008 Dec;93(12):4774-9. Epub 2008 Sep 30.PMID: 18826999 [PubMed - indexed for MEDLINE]Related articles

    5.

    Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

    Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M; Diabetes Prevention Program Research Group.

    Diabetes Care. 2005 Apr;28(4):888-94.PMID: 15793191 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

    Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Apr 19;142(8):611-9.PMID: 15838067 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Alcohol consumption and diabetes risk in the Diabetes Prevention Program.

    Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL; Diabetes Prevention Program Research Group.

    Am J Clin Nutr. 2009 Sep;90(3):595-601. Epub 2009 Jul 29.PMID: 19640960 [PubMed - indexed for MEDLINE]Related articles

    8.

    The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.

    Diabetes Prevention Program Research Group, Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, Dagogo-Jack S, Andres R.

    J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1075-81.PMID: 17077202 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

    Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; Diabetes Prevention Program Research Group.

    Diabetes. 2005 Aug;54(8):2404-14.PMID: 16046308 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Body size and shape changes and the risk of diabetes in the diabetes prevention program.

    Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, Hanson R, Hill JO, Hubbard V, Stamm E, Pi-Sunyer FX; Diabetes Prevention Program Research Group.

    Diabetes. 2007 Jun;56(6):1680-5. Epub 2007 Mar 15.PMID: 17363740 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Mar 1;142(5):323-32.PMID: 15738451 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.

    Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E; Diabetes Prevention Program Research Group.

    Diabetes. 2005 May;54(5):1566-72.PMID: 15855347 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.

    Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Numao T, Fukuda T, Shimada K, Kario K.

    Hypertens Res. 2007 Jan;30(1):23-30.PMID: 17460368 [PubMed - indexed for MEDLINE]Related articles

    14.

    Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

    Eddy DM, Schlessinger L, Kahn R.

    Ann Intern Med. 2005 Aug 16;143(4):251-64.PMID: 16103469 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program.

    Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME; Diabetes Prevention Program Research Group.

    Diabetes Care. 2006 Apr;29(4):914-9.PMID: 16567837 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program.

    Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM; DDK Research Group.

    Diabetes. 2007 Apr;56(4):1153-9.PMID: 17395752 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program.

    Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E; Diabetes Prevention Program.

    Diabetes Care. 2008 Jul;31(7):1416-21. Epub 2008 Mar 20.PMID: 18356403 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

    Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP).

    Diabetologia. 2006 Feb;49(2):289-97. Epub 2006 Jan 4.PMID: 16391903 [PubMed - indexed for MEDLINE]Related articles

    19.

    Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants.

    Rubin RR, Knowler WC, Ma Y, Marrero DG, Edelstein SL, Walker EA, Garfield SA, Fisher EB; Diabetes Prevention Program Research Group.

    Diabetes Care. 2005 Apr;28(4):830-7.PMID: 15793181 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.

    Harden KA, Cowan PA, Velasquez-Mieyer P, Patton SB.

    J Am Acad Nurse Pract. 2007 Jul;19(7):368-77.PMID: 17680902 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity